TY - JOUR
T1 - Malignant clinical features of anaplastic gliomas without IDH mutation
AU - Shibahara, Ichiyo
AU - Sonoda, Yukihiko
AU - Shoji, Takuhiro
AU - Kanamori, Masayuki
AU - Saito, Ryuta
AU - Inoue, Tomoo
AU - Kawaguchi, Tomohiro
AU - Yamashita, Yoji
AU - Watanabe, Takashi
AU - Kumabe, Toshihiro
AU - Watanabe, Mika
AU - Suzuki, Hiroyoshi
AU - Tominaga, Teiji
N1 - Publisher Copyright:
© The Author(s) 2014. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Background Diagnosis of WHO grade III anaplastic gliomas does not always correspond to its clinical outcome because of the isocitrate dehydrogenase (IDH) gene status. Anaplastic gliomas without IDH mutation result in a poor prognosis, similar to grade IV glioblastomas. However, the malignant features of anaplastic gliomas without IDH mutation are not well understood. The aim of this study was to examine anaplastic gliomas, in particular those without IDH mutation, with regard to their malignant features, recurrence patterns, and association with glioma stem cells. Methods We retrospectively analyzed 86 cases of WHO grade III anaplastic gliomas. Data regarding patient characteristics, recurrence pattern, and prognosis were obtained from medical records. We examined molecular alterations such as IDH mutation, 1p19q loss, TP53 mutation, MGMT promoter methylation, Ki67 labeling index, and CD133, SOX2, and NESTIN expression. Results Of the 86 patients with anaplastic gliomas, 58 carried IDH mutation, and 40 experienced recurrence. The first recurrence was local in 25 patients and distant in 15. Patients without IDH mutation exhibited significantly higher CD133 and SOX2 expression (P =. 025 and. 020, respectively) and more frequent distant recurrence than those with IDH mutation (P =. 022). Conclusions Patients with anaplastic gliomas without IDH mutation experienced distant recurrence and exhibited glioma stem cell markers, indicating that this subset may share some malignant characteristics with glioblastomas.
AB - Background Diagnosis of WHO grade III anaplastic gliomas does not always correspond to its clinical outcome because of the isocitrate dehydrogenase (IDH) gene status. Anaplastic gliomas without IDH mutation result in a poor prognosis, similar to grade IV glioblastomas. However, the malignant features of anaplastic gliomas without IDH mutation are not well understood. The aim of this study was to examine anaplastic gliomas, in particular those without IDH mutation, with regard to their malignant features, recurrence patterns, and association with glioma stem cells. Methods We retrospectively analyzed 86 cases of WHO grade III anaplastic gliomas. Data regarding patient characteristics, recurrence pattern, and prognosis were obtained from medical records. We examined molecular alterations such as IDH mutation, 1p19q loss, TP53 mutation, MGMT promoter methylation, Ki67 labeling index, and CD133, SOX2, and NESTIN expression. Results Of the 86 patients with anaplastic gliomas, 58 carried IDH mutation, and 40 experienced recurrence. The first recurrence was local in 25 patients and distant in 15. Patients without IDH mutation exhibited significantly higher CD133 and SOX2 expression (P =. 025 and. 020, respectively) and more frequent distant recurrence than those with IDH mutation (P =. 022). Conclusions Patients with anaplastic gliomas without IDH mutation experienced distant recurrence and exhibited glioma stem cell markers, indicating that this subset may share some malignant characteristics with glioblastomas.
KW - Anaplastic gliomas
KW - CD133
KW - Distant recurrence
KW - Grade III gliomas
KW - IDH
UR - http://www.scopus.com/inward/record.url?scp=84922547109&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922547109&partnerID=8YFLogxK
U2 - 10.1093/neuonc/nou112
DO - 10.1093/neuonc/nou112
M3 - Article
C2 - 24958096
AN - SCOPUS:84922547109
VL - 17
SP - 136
EP - 144
JO - Neuro-Oncology
JF - Neuro-Oncology
SN - 1522-8517
IS - 1
ER -